Left Atrial Appendage Closure Device

The WATCHMAN Left Atrial Appendage Closure Device is a proven alternative to long-term warfarin therapya for stroke risk reduction in patients with atrial fibrillation.

Key Resources

Product Brochure Patient Selection Brochure Patient Referral Brochure Patient Guide

Product Details

WATCHMAN with desciptions WATCHMAN with desciptions

Proof of Leadership

Stop the Stroke Where It Starts

The WATCHMAN™ LAA closure technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have contraindication to anti-coagulation therapy.

WATCHMAN™ Leadership

WATCHMAN™ Leadership WATCHMAN™ Leadership


Proximal Face Proximal Face

Proximal Face
Minimizes surface area facing the left atrium to reduce post-implant thrombus formation

Intra-LAA Design Intra-LAA Design

Intra-LAA Design
Unique intra-LAA design to avoid contact with the left atrial wall and prevent complications

Nitinol Frame Nitinol Frame

Nitinol Frame
Conforms to the unique anatomy of the LAA to reduce emoblization risk

Nitinol Frame

Engineered to conform to the unique anatomy of the LAA to reduce embolization risk1

Flexible strut design with fixation anchors to distribute radial force from the LAA wall

Self expanding nitinol framethat reaches its ideal shape once exposed to a patient‘s internal body temperature

Nitinol Frame Nitinol Frame

Intra-LAA Design

Unique Intra-LAA design to avoid Left Atrial complications such as erosion and interference with surrounding anatomy:1-3

  • Intra-LAA placement reduces risk of device erosion by avoiding contact with the Left Atrial wall
  • Intra-LAA placement minimizes the potential that the device may interfere with LUPV and Mitral Valve

Intra-LAA Design Intra-LAA Design

Proximal Face

Optimized proximal face design to minimize thrombus formation1-3

160 micron PET fabric intended to promote endothelialisation during healing process

Small proximal face and low profile screw to minimize the surface area where thrombus can form

Proximal Face Proximal Face

WATCHMAN™ Proven Results

  • Largest body of clinical evidence with seven studies (initial pilot study, two randomized clinical trials (PROTECT AF and PREVAIL), the ASAP, CAP, CAP 2 and EWOLUTION registries) which included more than 3,400 patients and nearly 6000 patient-years of clinical evidence specific to the WATCHMAN Device.
  • With over 4 years of follow-up, WATCHMAN™ continues to provide long-term stroke risk reduction without the need for long-term oral anti-coagulation therapy
  • Proven safe, effective and statistically superiora alternative to long-term warfarin therapy for primary efficacy

WATCHMAN Proven Results WATCHMAN Proven Results